Overview
Module 4 of the Joint DIA/MEB "Excellence in Pharmacovigilance" virtual live training course is dedicated to Risk Management.
In accordance with the GVP Module V on Risk Management System, Risk Management Plans (RMPs) should be submitted by companies to propose activities aiming to identify, characterise or minimise risks associated with medicinal products. Given the potential public health implications and costs of such interventions, RMPs should be based on robust data. Examples will be discussed in this module.
Nonetheless, specific data collection and analysis are desirable for some safety issues, and pharmaco-epidemiological studies are the most performed tools of those “additional” Pharmacovigilance activities. This module also presents recent developments regarding risk communication.
- "Excellence in Pharmacovigilance" Module 1: Post-Marketing
- "Excellence in Pharmacovigilance" Module 2: Safety Aspects in Clinical Trials
- "Excellence in Pharmacovigilance" Module 3: Quality Management System
- "Excellence in Pharmacovigilance" Module 4: Risk Management
- "Excellence in Pharmacovigilance" Module 5: Signal Management
Program Committee
-
Wendy Huisman, PharmD Director
Vigifit, Netherlands -
Fakhredin Sayed Tabatabaei, MD, PhD Senior Assessor
MEB, Netherlands
Have an account?